Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3847732 | 0.93 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| Bromide SCHEMBL6010080 | 0.91 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| Bromide SCHEMBL6075032 | 0.88 | NPC1 (0.52) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| Bromide SCHEMBL3848906 | 0.86 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| Bromide SCHEMBL3845955 | 0.81 | HTT (0.49) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL28307818 | 0.80 | GSK3B (0.51) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| Bromide SCHEMBL3852051 | 0.76 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2216212 | 0.72 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL711360 | 0.72 | RAB9A (0.75) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| Bromide SCHEMBL6074363 | 0.72 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022721-B1 | Method and composition for rejuvenating cells, tissues, organs, hair and nails | ULRICH PETER C | 2006-04-04 | — | — | US | disclosed |
| EP-1368029-A4 | METHOD AND COMPOSITION FOR REJUVINATING CELLS, TISSUES, ORGANS, HAIR AND NAILS | FARRINGTON PHARMACEUTICALS LLC (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20050245512-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | ULRICH PETER C | 2005-11-03 | — | — | US | disclosed |
| US-6777557-B2 | Method and composition for rejuvenating cells, tissues organs, hair and nails | FARRINGTON PHARMACEUTICALS, LLC | 2004-08-17 | — | — | US | disclosed |
| EP-1368029-A2 | METHOD AND COMPOSITION FOR REJUVINATING CELLS, TISSUES, ORGANS, HAIR AND NAILS | Farrington Pharmaceuticals, LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20020188015-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | FARRINGTON PHARMACEUTICALS, LLC | 2002-12-12 | — | — | US | disclosed |
| WO-2002062301-A2 | METHOD AND COMPOSITION FOR REJUVINATING CELLS, TISSUES, ORGANS, HAIR AND NAILS | FARRINGTON PHARMACEUTICALS, LLC (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188015-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | TERT, TELO2, HKDC1 | ALDH1A1 3396/4885MEN1 2886/4885KMT2A 1145/4885 |
| US-20050245512-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | TERT, TELO2, HKDC1 | ALDH1A1 3396/4885MEN1 2886/4885KMT2A 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.